New Virttu Replicate Open Innovation Forum Provides Unique R&D Network for New Oncology Combination Therapies  
11/5/2012 10:01:14 AM

GLASGOW, Scotland--(BUSINESS WIRE)--Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced the launch of the Virttu REPLICATE™ Open Innovation Forum. Accessible to researchers in institutes and biotechnology and pharmaceutical companies, the REPLICATE Open Innovation Forum aims to stimulate development of new oncology combination therapies by providing access to Virttu’s oncolytic virus, SEPREHVIR™ (HSV1716).